Raising Awareness of CAR T Therapy for Mantle Cell Lymphoma: Luhua Wang, MD


The professor from The University of Texas MD Anderson Cancer Center discussed growing awareness of CAR T-cell therapy among community oncologists and patients with mantle cell lymphoma.

This content originally appeared on our sister site, Targeted Oncology.

Targeted Oncology spoke with Michael Luhua Wang, MD, professor in the Department of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, to learn more about the growing awareness of chimeric antigen receptor (CAR) T-cell therapy among community oncologists and patients with mantle cell lymphoma (MCL).

Wang discussed the potential of CAR T-cell therapies, which modify the patient’s T cells to target the CD19 protein expressed in cancer cells and can lead to long-term remission in patients with advanced MCL.

CAR-T cell therapy using brexucabtagene autoleucel (Tecartus) was approved in July 2020 for patients with relapsed or refractory MCL, based on the ZUMA-2 clinical trial led by Wang. In the trial, 87% of patients had a response to CAR T-cell therapy and 62% had a complete response. While CAR T-cell treatments have a high toxicity, the study showed that it can be balanced to achieve remission.

According to Wang, some oncologists continue to use other therapies in advanced MCL, which including autologous stem cell transplant and chemoimmunotherapy. However, he says that awareness of CAR T-cell therapy is spreading. Community oncologists are now better informed about its efficacy and safety, and in addition, patients and their families are seeking out specialists when they learn about the availability of the therapy.


0:08 | Since the approval a little more than a year ago, I have started receiving referrals from the community oncologists for their patients to be considered [for] CAR T-cell therapy. I think yes, there are still oncologists using the older therapies. But I think the knowledge gap is closing very rapidly and everybody has heard about the CAR T cells. Sometimes, before the doctors realize, the patient already requested it, and the patient is in a very educated population. The patient, and very likely their young families, are searching the computer, Google, the web, all the time for knowledge of MCL, [for] new therapies, and [they have] contacted people like me and other doctors for us to see their family members with MCL. I really think that [news of] the CAR T-cell therapies’ efficacy and safety will continue to spread, [and] the usage of it will continue to rise. So I think the future is bright.

Related Videos
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
Maria Escolar, MD, the chief medical officer of Forge Biologics
Casey Maguire, PhD, associate professor of neurology and associate investigator of neurology, Harvard Medical School
Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics
© 2024 MJH Life Sciences

All rights reserved.